Exomes of 22 DIPG primary tumors were sequenced to identify somatic mutations and copy number alterations. Tumors with matched normal tissue are indicated by an "M", while those without matched normal tissue are indicated by a "U" in the second row of each heatmap. In (a), the mutation landscape has been restricted to highly-recurrent aberrations, while in (b), the mutation landscape has been restricted to genes targeted by top hits from the drug screen. Color key: pink = gain; red = focal gain; light blue = loss; royal blue = focal loss; yellow = point mutation; green = indel/stop mutation/ splice site mutation; rightward sloping hatched lines = additional point mutation. Figure S2 : Chemical screen 'hits' within the context of clinically-achievable serum drug levels.
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Supplementary Figure 2. Chemical screen 'hits' within the context of clinicallyachievable serum drug levels. Box and whisker plot demonstrating the average absolute IC 50 values ("box") +/-1.5 standard deviation ("whiskers") for each of the top "hits", listed on the vertical axis, with concentration in M on the horizontal axis. C max (the peak serum concentration reported in the literature) for each drug is represented as a red bar. Open circles represent data points more than two standard deviations from the mean. The number of cell lines responding to each agent (out of the number of cells lines tested for that agent) at an IC 50 value less than that drug's C max is indicated to the left of the plot. For example, if 10 of 14 cell lines responded to panobinostat with an IC 50 < C max, that is indicated as 10/14. Only those drugs that were "hits" in three or more cell lines are shown.
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.57 .71 CAMK2A  CAMK1G  EPHB6  TNIK  HDAC11   TEK  CAMK2G  ANKK1  HSP90AA2   HIPK3  CAMK2B  MAPK10  HIPK4  MINK1  PRKCG  TAOK3  PLK1  CHEK2  TGFBR1  KDM4B  CSK  MAP2K3  CDKN2A  DAXX  DAPK3  PIP5K1A  H3F3A  NRAS  IKBKB  CDK3  BIRC5  HTRA2  EPHB3  CCND1  MYC  CDK4  AKT2  OXSR1  CDK2  STK10  CD276  PSMB8  ACVR1  WEE1 A and B) were tested to control for offtarget effects. The combination of shHDAC1 and shHDAC2 was also tested in comparison to shHDAC1 or shHDAC2 individually. Data shown as mean ± SD. (e) DIPG cells infected with lentivirus expressing shCtrl, the two alternate shHDAC1 or the two alternate shHDAC2 were seeded in triplicate into 96-well plates and cell viability was assessed using the CelltiterGlo assay at 0, 3 and 5 days. Data are expressed relative to Day 0 and are shown as mean ± SD. (f) DIPG cells infected with lentivirus expressing shHDAC1 and shHDAC2 together or individually were seeded in triplicate into 96-well plates and cell viability was assessed using the CelltiterGlo assay at 0, 3 and 5 days. Data are expressed relative to Day 0 and are shown as mean ± SD respectively. Two-tailed ttests were used in (a) and (b). Two-way ANOVAs were used in (c) and (d). ***P < 0.001 DIPG-luc cells were set in multiple wells of 96-well plate and treated with 0.1% DMSO or panobinostat at 0.1 or 0.5 M for 48 hours. Then, half of the wells were subjected to the CelltiterGlo assay for assessing cell viability while the other half were subjected to the luciferase assay for assessing luciferase activity. Relative luciferase unit was calculated as the ratio between luciferase activity and cell viability in duplicate or triplicate to assess relative luciferase activity at a per cell level. Data shown as mean ± SD. *P < 0.05; ***P < 0.001 (two-tailed t test). (b) Replicate experiment demonstrating CED delivery of panobinostat inhibits DIPG orthotopic xenograft growth. As in the experiment described in Fig. 2 , NOD-SCID-IL2R-gamma chain deficient mice were implanted with 100,000 SU-DIPG-VI-luc cells in the brainstem at postnatal day 2 (P2) and allowed to engraft for 2 months prior to treatment with a single dose of panobinostat delivered by CED. The data show DIPG xenograft tumor growth in vivo as measured by change in bioluminescent photon emission over the seven days following CED delivery of panobinostat (panobinostat group, blue squares) or vehicle control (Control group, red circles). Data points represent fold change in maximum photon flux between Day 0 and Day 7 for each mouse; each data point represents one mouse. n = 8 control, 9 treated mice. Error bars, s.e.m. *P < 0.05 (twotailed t test) (c) Systemic delivery of panobinostat inhibits tumor growth in a DIPG orthotopic xenograft in vivo. SU-DIPG-VI-luc xenograft tumor growth as measured by change in bioluminescent photon emission over 25 days following weekly systemic delivery of panobinostat (panobinostat group, red squares) or vehicle control (Control group, blue circles). Data points represent the fold change in maximum photon flux between Day 0 and Day 25 for each mouse; each data point represents one mouse. In total, four doses of panobinostat 20 mg/kg i.p. were given. n = 7 mice in each group. Error bars, s.e.m. *P < 0.05 (two-tailed t test). 
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